Seizures Clinical Trial
Official title:
Phase I/II Study of IV Levetiracetam as an add-on Drug for Seizures in Term Neonates Assessing Pharmacokinetics, Safety and Efficacy.
The purpose of this study is to determine the correct dosing for intravenous levetiracetam in term new born babies with seizures. In addition information on safety and efficacy will be collected. This new anticonvulsant drug is a promising treatment for seizures in newborns.
There is a pressing need to improve the treatment of seizures in the neonatal period. The
anticonvulsant agents currently in use may damage the developing brain and are quite
ineffective at controlling seizures in neonates. Newborn seizures are common (1 in 300
newborns) and are associated with very poor outcomes. 20-30% of infants with neonatal
seizures die, 20-30% develop epilepsy outside the neonatal period and 20-40% develop
cerebral palsy and/or mental retardation. Better treatments for neonatal seizures could
improve these outcomes.
An intravenous form of the anti-seizure medication levetiracetam has been released for use
in adults with epilepsy. Experience with oral levetiracetam has shown it to be a very safe
medication, with good efficacy in stopping seizures in other age groups. The intravenous
preparation could allow its use in neonates with seizures. Drug handling by the body is very
different in neonates to adults. Before we can use levetiracetam in this age group we need
to determine the correct dose and frequency by studying its absorption and distribution in
the body (pharmacokinetic profile).
This study is an add-on open label pharmacokinetic and preliminary safety study. Twenty-four
patients with neonatal seizures, who still experience clinical or electroencephalographic
seizures after treatment with Phenobarbital will be treated with intravenous levetiracetam,
and serial determinations of serum levetiracetam levels will be made to allow calculation of
pharmacokinetic parameters. We will also collect preliminary safety data. We will
specifically monitor for abnormalities of heart rate, respiratory rate and blood pressure,
unexpected death, the occurrence of hypotonia, sedation, poor feeding, irritability or
infection. Blood tests monitoring blood, liver and kidney function will be checked at
baseline, 48 hours and at completion of 7 days of treatment. We will also collect
preliminary descriptive data on the efficacy of levetiracetam in stopping neonatal seizures.
;
Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02850913 -
Doxycycline for the Treatment of Nodding Syndrome
|
Phase 2 | |
Recruiting |
NCT04076449 -
Quantitative Susceptibility Biomarker and Brain Structural Property for Cerebral Cavernous Malformation Related Epilepsy
|
||
Not yet recruiting |
NCT06045676 -
Electrocardiographic Changes Among Epileptic and Non Epileptic Seizures in Children at Sohag University Hospital
|
||
Completed |
NCT03722212 -
Early Diagnosis of the GLUT1 Deficiency Syndrome With a Blood Based Test
|
N/A | |
Not yet recruiting |
NCT05649891 -
Checklists Resuscitation Emergency Department
|
N/A | |
Completed |
NCT02897856 -
Efficacy and Safety of Intramuscular Midazolam Compared to Buccal Midazolam in Pediatric Seizures
|
Phase 4 | |
Completed |
NCT01236001 -
Belgian Drug-utilization Study to Evaluate the Use of VIMPAT® as Adjunctive Treatment of Partial Onset Seizures in Subjects Aged 16 and Older
|
N/A | |
Completed |
NCT01239212 -
Dosing of Levetiracetam (Keppra) in Neonates
|
Phase 1/Phase 2 | |
Completed |
NCT01703468 -
Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fed Conditions
|
Phase 1 | |
Completed |
NCT01702623 -
Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fasted Conditions
|
Phase 1 | |
Recruiting |
NCT02216500 -
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
|
N/A | |
Completed |
NCT00236717 -
A Study of the Effectiveness and Safety of Topiramate Compared With a Standard Therapy in Patients Newly Diagnosed With Epilepsy
|
Phase 3 | |
Terminated |
NCT03954314 -
DEPOSITION - Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery
|
Phase 3 | |
Completed |
NCT05103735 -
Propofol-remifentanyl Versus Dexmedetomidine in Awake Craniotomy: Impact on Electroclinical Seizure Activity
|
||
Terminated |
NCT03790436 -
Betaquik as an Adjunct to Dietary Management of Epilepsy in Adults on the Modified Atkins Diet
|
N/A | |
Completed |
NCT06451289 -
Study on Optic Nerve Sheath Diameter Measurements in Prolonged Pediatric Seizures
|
||
Recruiting |
NCT02552511 -
Epidemiology Study on Neonatal Seizure
|
||
Recruiting |
NCT05339126 -
RNS System LGS Feasibility Study
|
Phase 2 | |
Active, not recruiting |
NCT04595786 -
The Safety of Intravenous Tranexamic Acid in Patients Undergoing Supratentorial Meningiomas Resection
|
N/A | |
Recruiting |
NCT04770337 -
Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy
|
N/A |